🇺🇸 didanosine + lamivudine + efavirenz in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 3
Most-reported reactions
- Diarrhoea — 1 report (33.33%)
- Drug Ineffective — 1 report (33.33%)
- Isosporiasis — 1 report (33.33%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is didanosine + lamivudine + efavirenz approved in United States?
didanosine + lamivudine + efavirenz does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for didanosine + lamivudine + efavirenz in United States?
Clinical Trial Agency of HIV Study Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.